-- Livzon Pharmaceutical Group's (SHE:000513, HKG:1513) obtained approval to conduct a clinical trial of JP-1366 Tablet from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The approval is for the indication of the combination of the drug with appropriate antibiotics for the eradication of Helicobacter pylori.